biostudies-literatureMiller KENCINCRR NIH HHSNationwide Insurance Innovation FundNCI NIH HHSNIH498-506https://www.ebi.ac.uk/biostudies/studies/S-EPMC8846434biostudies-literatureUnknown28(3)<h4>Purpose</h4>Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demonstrated that inoculation with a conditionally replication-competent Δγ₁34.5 oncolytic herpes simplex virus (oHSV), G207, was safe. Following the initial safety study, a phase Ib trial enrolled 6 adult patients diagnosed with GBM recurrence from which tumor tissue was banked for future studies.<h4>Patients and methods</h4>Here, we analyzed tumor RNA sequencing (RNA-seq) data obtained from pre- and posttreatment (collected 2 or 5 days after G207 injection) biopsies from the phase Ib study patients.<h4>Results</h4>Using a Spearman rank-order correlation analysis, we identified approximately 500 genes whose expression pattern correlated with survival duration. ManClinical cancer research : an official journal of the American Association for Cancer ResearchImmune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.PMC8846434P01 CA071933R01 CA217179U54 CA232561R01-CA217179U54-CA232561R01 CA222903R01-CA222903M01 RR000032Cassady KAMiller ARPrasad NLeavenworth JWClements JMiller KEAban IBGillespie GYRoth JCMardis ERMarkert JMSchieffer KMWhitley RJLeraas KfalseImmune Activity and Response Differences of Oncolytic Viral Therapy in Recurrent Glioblastoma: Gene Expression Analyses of a Phase IB Study.<h4>Purpose</h4>Previously, clinical trials of experimental virotherapy for recurrent glioblastoma multiforme (GBM) demonstrated that inoculation with a conditionally replication-competent Δγ₁34.5 oncolytic herpes simplex virus (oHSV), G207, was safe. Following the initial safety study, a phase Ib trial enrolled 6 adult patients diagnosed with GBM recurrence from which tumor tissue was banked for future studies.<h4>Patients and methods</h4>Here, we analyzed tumor RNA sequencing (RNA-seq) data obtained from pre- and posttreatment (collected 2 or 5 days after G207 injection) biopsies from the phase Ib study patients.<h4>Results</h4>Using a Spearman rank-order correlation analysis, we identified approximately 500 genes whose expression pattern correlated with survival duration. Man2022-01-01T00:00:00Z2022 Feb2026-05-31T02:35:36.01Z2025-04-07T04:06:24.381ZS-EPMC88464343510571810.1158/1078-0432.CCR-21-2636